Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Category Deep Dive on Dialysis

Dialysis is a necessary procedure that allows nearly 500,000 patientsin the United States with kidney failure the opportunity to live normal, productive lives. The treatment removes waste, salt, and extra water when the native kidneys are no longer able. Though there are several types of dialysis, the most common is Hemodialysis, in which blood is removed from the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Dialysis is a necessary procedure that allows nearly 500,000 patientsin the United States with kidney failure the opportunity to live normal, productive lives. The treatment removes waste, salt, and extra water when the native kidneys are no longer able. Though there are several types of dialysis, the most common is Hemodialysis, in which blood is removed from the body, run through a dialyzer, cleaned, and replaced into the body. Dialysis takes three hours to complete and is offered by health systems as inpatient and outpatient treatments.

The federal government pays 80% of all dialysis costs for most patients via Medicare. In fact, the dialysis industry experienced large significant in 1972 when procedures became covered through this program. The industry is run on a for-profit basis, with the market being dominated by two large publicly traded companies known as DaVita and Fresenius. Smaller communities and rural healthcare organizations are more likely to turn to the many local and regional dialysis service providers. Additionally, hospitals or treatment centers must assess the option of operating their own dialysis center for maximum convenience to their patients.

Technology is available to help determine every cost within every purchased services expense category of a health system, revealing massive savings potential in important areas, including dialysis. Here are several factors that healthcare providers should know about dialysis when considering opportunities for savings.

  • The Need for Dialysis is Going Up: The number of patients requiring End Stage Renal Dialysis treatment is increasing each year, with mortality rates depending on the treatment. ESRD, or renal failure, is the fastest-growing cause of hospitalizations, and the fifth leading reason for readmissions.
  • Dialysis Is a Competitive Business. With multiple options usually available for health systems, it’s essential to ensure your organization has evaluated them all recently. Joint ventures between hospitals or health systems and dialysis providers are common. A patient’s choice in healthcare provider and dialysis company are critical factors in driving usage of centers.
  • Savings Opportunities Exist in the Cost of Smaller Purchased Services: Ongoing dialysis treatments can be categorized into purchased services, which is any service contracted and performed by a third party as opposed to the in-house staff at the hospital. Purchased services can account for up to 45% of an average U.S. hospital’s non-labor expenses. However, most health systems continuously tackle savings within the larger categories only, including food, EVS, and blood, ignoring the smaller purchased services categories.
  • Categorize the Entire Spend in a System: Without categorizing their entire purchased services spend and prioritizing opportunities, health systems are missing out on addressing smaller categories—including dialysis—that still have large savings opportunities. Why? Without technology, many systems are not able to categorize their entire organization’s spend and prioritize these kinds of opportunities.

Effective Category Monitoring Helps Health Systems Thrive

By prioritizing opportunities and categorizing purchased service costs, health systems will no longer fail to acknowledge dialysis and other smaller categories. Hospitals and healthcare systems using purchased services expense management technology can identify areas of financial improvement in smaller categories like dialysis by utilizing software that not only identifies but breaks down purchased services and reveals a deeper understanding of the overall costs.

Many Americans require dialysis treatment; however, it is an often-ignored category within purchases services that has potential for great savings. At Valify, we offer a breakthrough technology that uses innovative tools to reveal savings opportunities for each expense, saving hospitals 20-30% per purchased service category, on average.

To discover how our technology platform operates, request a live demo at getvalify.com/demo-valify.

Read more at getvalify.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512